Sividon Diagnostics GmbH
San Antonio Breast Cancer Symposium 2015: EndoPredict prognostic after neoadjuvant chemotherapy and superior to commonly used markers
If a breast cancer tumour is still detectable after neoadjuvant chemotherapy, this does not necessarily imply a less favourable prognosis. Using the EndoPredict(R) gene expression test, these patients can be stratified into two risk groups: Those at high risk and those at low risk of recurrence. In a comparison in the context of the GeparTrio study by the German Breast Group (GBG), the EndoPredict hybrid score EPclin was found clearly superior to the CPS-EG score otherwise relevant for clinical studies. The results were now presented at this year’s San Antonio Breast Cancer Symposium.
“The prognosis after application of chemotherapy is relevant for the question which patients are optimally treated with chemo-endocrine therapy and for which cases use of new agents is particularly indicated,” explains Prof. Dr. Sibylle Loibl, Co-Chair of the German Breast Group. “These women in particular should be offered the opportunity to participate in ‘post-neoadjuvant’ trials.” Currently, it is common practice to assess the cases according to the so-called CPS-EG staging system. This combines clinical tumour stage prior to neoadjuvant therapy (CS), pathological tumour stage after neoadjuvant treatment (PS), grading (G) and oestrogen receptor status (E). A direct comparison between the CPS-EG system and the EPclin score consisting of the molecular EndoPredict score, nodal status, and tumour size, showed that only the EPclin was significantly associated with lower rates of disease-free survival. Similar results were obtained for overall survival. Tumour samples from patients who had been treated with neoadjuvant chemotherapy (TAC or TAC-NX) during the GeparTrio trial were analysed. Only hormone receptor-positive and HER2/ neu-negative tumour samples were considered. The EndoPredict test was carried out following the chemotherapy on the surgical resectate. Sividon Diagnostics GmbH was founded in July 2010 as a management buyout from Siemens Healthcare Diagnostics Products in Cologne, Germany. The company aims to sustainably increase the quality of therapy-accompanying diagnostics in oncology. EndoPredict(R), the first diagnostic test from Sividon, has been available since 2011. The breast cancer prognostic test helps in deciding for which patient a chemotherapy is indicated End of Media Release Issuer: Sividon Diagnostics GmbH Key word(s): Health 12.12.2014 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
305073 12.12.2014 |